Crown Electrokinetics CORP 8-K filings

Current reports — the filing a company makes when something happens that shareholders need to know about before the next quarterly report.

OTC.Pink
Crown Electrokinetics Corp. has amicably terminated its engagement with Frank, Rimerman + Co. LLP and appointed CBIZ CPAs P.C. as its new independent registered public accounting firm, effective January 12, 2026.
OTC.Pink
Crown Electrokinetics' subsidiary, Crown Fiber Optics Corp., sold its fiber optics and construction assets to Paramount Infrastructure Corp. for $2 million.
OTC.Pink
Crown Electrokinetics Corp. announced the resignation of Joel Krutz from its Board of Directors and his subsequent termination as Chief Operating Officer and Chief Financial Officer.
OTC.Pink
Crown Electrokinetics Corp. has engaged Frank, Rimerman + Co. LLP as its independent registered public accounting firm for the 2025 fiscal year.
OTC.Pink
Crown Electrokinetics Corp. announced the appointment of Chris Robichaud to its Board of Directors, who will also chair the Audit Committee.
OTC.Pink
Crown Electrokinetics Corp.'s independent auditor, BPM LLP, has resigned effective August 1, 2025, though not due to fraud or legal violations, while the company seeks a replacement.
OTC.Pink
Crown Electrokinetics Corp. and Crown EK Acquisition LLC have mutually agreed to terminate their previously announced merger agreement, which included a cash tender offer of $3.15 per share.
OTC.Pink
Crown Electrokinetics Corp. has amended its merger agreement, extending the deadline for the tender offer and associated deposits to July 15, 2025, and receiving a $500,000 promissory note from the acquiring entities and its CEO as a financial guarantee.
OTC.Pink
Crown Electrokinetics Corp. announced the resignation of Daniel Marcus from its Board of Directors and all associated committees, effective July 1, 2025.
OTC.Pink
Crown Electrokinetics Corp. has entered into a definitive merger agreement to be acquired by Crown EK Acquisition LLC, an entity controlled by its CEO Douglas Croxall, for $3.15 per share in cash.
OTC.Pink
Crown Electrokinetics Corp. has filed a Certificate of Designations to create Series G Preferred Stock, granting the holder 51% of the company's total voting power.
OTC.Pink
Crown Electrokinetics Corp. terminated its Common Stock Purchase Agreement with Liqueous, LP due to Liqueous' failure to timely pay amounts owed to the Company.
OTC.Pink
Crown Electrokinetics Corp. announces the resignation of Andrew Andy Mayer, President of Construction, effective March 25, 2025.
OTC.Pink
Crown Electrokinetics Corp. receives a delisting determination from Nasdaq and intends to request reconsideration and appeal the decision.
OTC.Pink
Crown Electrokinetics Corp. has announced a 1-for-150 reverse stock split effective January 30, 2025, to maintain its Nasdaq listing and position the company for long-term growth.
OTC.Pink
Crown Electrokinetics Corp. announces shareholder approval for a reverse stock split and ratification of its accounting firm at a special meeting on January 14, 2025.
OTC.Pink
Crown Electrokinetics Corp. has received a delisting notice from Nasdaq due to its share price falling below the required minimum of $1.00, and the company plans to request a hearing to appeal the decision.
OTC.Pink
Crown Electrokinetics Corp. has entered into a stock purchase agreement with Liqueous, LP, allowing the company to sell up to $100 million of its common stock over a 24-month period.
OTC.Pink
Crown Electrokinetics Corp. filed an amended 8-K to include a previously omitted auditor consent from Marcum LLP, which does not impact previously reported financials.
OTC.Pink
Crown Electrokinetics Corp. filed an amendment to its 8-K report to include a letter from its former auditor, Marcum LLP, confirming their agreement with the company's statements regarding the auditor change.
OTC.Pink
Crown Electrokinetics Corp. has dismissed Marcum LLP as its independent auditor and engaged BPM LLP, effective August 13, 2024.
OTC.Pink
Crown Electrokinetics has successfully regained compliance with Nasdaq's minimum bid price requirement, ensuring its continued listing on the exchange.
OTC.Pink
Crown Electrokinetics has appointed Robert Vandal as its new Chief Technology Officer and transitioned Tim Koch to Chief Innovation Officer, effective July 8, 2024, to accelerate product development and market delivery.
OTC.Pink
Crown Electrokinetics Corp. has announced a 1-for-150 reverse stock split, effective June 24, 2024, to be implemented to maintain its NASDAQ listing.
OTC.Pink
Crown Electrokinetics Corp. held its annual meeting on June 14, 2024, where shareholders voted on key proposals including the election of directors, ratification of auditors, a reverse stock split, and approval of an employee incentive plan.
OTC.Pink
Crown Electrokinetics has received an extension from Nasdaq to meet listing requirements, with a deadline of July 23, 2024.
OTC.Pink
Crown Electrokinetics Corp. has amended its bylaws to lower the quorum requirement for stockholder meetings to one-third of voting power, effective May 27, 2024.
OTC.Pink
Crown Electrokinetics Corp. has amended the terms of its Series A, B, and C preferred stock, reducing the conversion price to $0.0462 per share and aligning dividend rights with common stock payouts.
OTC.Pink
Crown Electrokinetics has scheduled its 2024 annual meeting for June 14, 2024, with a May 14, 2024 record date and a May 15, 2024 deadline for shareholder proposals.
OTC.Pink
Crown Electrokinetics Corp. has hired Sheldon Davis as President of its Electrokinetic Film division, effective April 24, 2024, to lead the company's smart glass technology initiatives.